Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking approval for its investigational Bruton's tyrosine kinase (BTK) inhibitor, ...
Corcept Therapeutics has shown unexpected KORLYM franchise durability despite generic pressure and legal headwinds. Relacorilant's transition plan faltered after an FDA CRL, delaying lifecycle ...
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
REDWOOD CITY, Calif., December 31, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...
A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.
Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision. The US regulator has turned down J&J's marketing ...
Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), seeking approval for its proprietary, selective cortisol modulator, ...
Hosted on MSN
What makes Charles River (CRL) a new buy stock
Charles River Laboratories (CRL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Charles River Laboratories (CRL) has delivered a 28.49% change over the past year, with a 52-week range between 91.86 and 228.88. What Is the Average Daily Trading Volume of Charles River Laboratories ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback